[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Botkin Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":97},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100648768","renal-artery-pseudoaneurysm-after-pcnl-100648768",false,"NCT07724912","Renal Artery Pseudoaneurysm After PCNL","Risk Factors, Clinical Features and Outcomes of Management for Renal Artery Pseudoaneurysm After PCNL: A Multicenter Retrospective Study","Inclusion Criteria:\n\nAge ≥18 years\n\nUnderwent percutaneous nephrolithotomy (PCNL)\n\nRenal artery pseudoaneurysm confirmed by CT angiography\n\nFollow-up ≥30 days post-procedure\n\nExclusion Criteria:\n\nKnown pre-existing renal vascular anomalies or abnormalities\n\nIncomplete medical records (missing key data for analysis)","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","1 Year","OBSERVATIONAL","In a multicenter retrospective study, to assess the incidence and risk factors of renal artery pseudoaneurysm after percutaneous nephrolithotomy, and to characterize the clinical presentation and treatment outcomes.",[25],"Artery Pseudoaneurysm After PCNL",[27],"Renal artery pseudoaneurysm, percutaneous nephrolithotomy, PCNL, retrospective multicenter study, risk factors, incidence, endovascular embolization","NOT_YET_RECRUITING","2026-07-20",{"date":31,"type":32},"2026-07-24","ACTUAL",{"date":34,"type":20},"2026-09-09",{"date":36,"type":20},"2027-05-29",{"name":38,"class":39},"Botkin Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100602469","studies-on-adsorption-international-learning-initiative-global-100602469","NCT07123909","Studies on Adsorption International Learning Initiative Global","The Use of Sorption Technologies in Patients Receiving Program Hemodialysis With Inflammatory Syndrome","SAILING","Inclusion Criteria:\n\n1. Adequate dialysis defined by a KT\u002FV index ≥ 1.4\n2. No active inflammatory process or infection\n3. Age ≥ 18 years\n4. Receiving standard hemodialysis regimen three times weekly, at least 4 hours per session\n5. Participants with elevated interleukin-6 (IL-6) and\u002For C-reactive protein (CRP) levels exceeding local laboratory reference values\n\nExclusion Criteria:\n\n1. Current use of steroids or immunosuppressive therapy\n2. History of kidney transplantation\n3. Diagnosis of cancer\n4. Pregnancy",{"count":49,"type":20},60,"INTERVENTIONAL",[52],"NA","Use of sorption technologies in patients undergoing maintenance hemodialysis with inflammatory syndrome and clinical manifestations of uremia",[55,56,57,58,59,60,61,62],"CKD (Chronic Kidney Disease) Stage 5D","Uremia; Chronic","Uremic; Toxemia","Inflammation Chronic","Hemodialysis","Inflammation Biomarkers","Dialysis Related Complication","Anemia Associated With End Stage Renal Disease",[64,65,66],"Program dialysis","Sorption","Complications of program dialysis","RECRUITING","2025-12-03",{"date":70,"type":32},"2025-12-10",{"date":72,"type":32},"2025-06-01",{"date":74,"type":20},"2026-06-30",{"name":38,"class":39},1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":50,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":76},"100597292","finerenone-in-patients-with-iga-nephropathy-prospective-interventional-trial-100597292","NCT07056595","Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial","Inclusion Criteria:\n\n* Adults (\\> 18 years) with the primary IgAN diagnosed by kidney biopsy;\n* Treatment with stable doses of iRAS or\u002Fand iSGLT2 inhibitors for at least 3 months prior inclusion into the trial;\n* Blood pressure \\\u003C 140\u002F90 mm Hg\n* 24-hour urinary albumin excretion \\> 300 mg\n\nExclusion Criteria:\n\n* Kidney transplantation in medical history\n* Chronic hepatic disease, including hepatitis, malignant tumor, active malignancy;\n* Heart failure with ejection fraction \\\u003C40%;\n* Acute myocardial infarction and\u002For stroke less then 3 months before including in trial;\n* Presence ANCA in serum\n* Ongoing immunosuppressive treatment\n* eGFR \\\u003C 20 ml\u002Fmin\n* Pregnancy and breastfeeding\n* Uncontrolled blood pressure",{"count":84,"type":20},30,[52],": IgA-nephropathy is the most common glomerulonephritis with the unfavorable prognosis in patients with persistent albuminuria. Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist that has demonstrated efficacy in reducing albuminuria in patients with CKD and type 2 diabetes in two major trials, FIGARO-DKD and FIDELIO. This finding supported the approval of finerenone by the U.S. Food and Drug Administration (FDA) for the treatment of chronic kidney disease (CKD). A subgroup analysis in the pooled FIDELITY trial demonstrated that in patients with CKD stages 1-4 and type 2 diabetes (T2D), the cardio- and nephroprotective effects of finerenone were independent of concomitant therapy with SGLT-2 inhibitors or GLP-1 receptor agonists. Thus, the role of finerenone in slowing CKD progression in T2D can be considered well-established. Given its albuminuria-reducing effects, finerenone is being investigated in multiple trials, including studies on non-diabetic kidney disease and IgA nephropathy, though no published results are available yet. In this trial finerenone will be used as a nephroprotective agent above standard treatment in terms of assessing adverse events and potential efficacy.",[88],"IgA Nephropathy (IgAN)","2025-06-30",{"date":91,"type":32},"2025-07-09",{"date":93,"type":32},"2025-05-21",{"date":95,"type":20},"2026-05-21",{"name":38,"class":39},""]